Ioannis Gounaris | LinkedIn
Ioannis GOUNARIS | Merck, Darmstadt | Pharmaceuticals | Research profile
Ioannis Gounaris | LinkedIn
Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 ...
Ioannis Gounaris's Email & Phone - The Queen Elizabeth Hospital King's Lynn NHS Foundation Trust
Ioannis Gounaris's Email & Phone - The Queen Elizabeth Hospital King's Lynn NHS Foundation Trust
Ioannis Gounaris | LinkedIn
Ioannis Gounaris | LinkedIn
Pavel MOZGUNOV | Advanced Research Fellow | PhD in Statistics | University of Cambridge, Cambridge | Cam | MRC Biostatistics Unit | Research profile
Ioannis GOUNARIS | Merck, Darmstadt | Pharmaceuticals | Research profile
Ιωάννης Σ. Κολιόπουλος: Η Ιστορία και οι χρήσεις της – Clio Turbata
Ioannis GOUNARIS | Merck, Darmstadt | Pharmaceuticals | Research profile
Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial - The Lancet Oncology
Ioannis GOUNARIS | Merck, Darmstadt | Pharmaceuticals | Research profile
Ioannis Gounaris | LinkedIn
Ioannis Gounaris | LinkedIn
Ioannis GOUNARIS | Merck, Darmstadt | Pharmaceuticals | Research profile
Ioannis Gounaris (GRE) :: Photos :: playmakerstats.com
Lesson of the month 2: Cauda equina in Cushing's syndrome | RCP Journals
Ioannis Gounaris | LinkedIn
Ioannis GOUNARIS | Merck, Darmstadt | Pharmaceuticals | Research profile
